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Purpose: Dual diagnosis (DD) is the co-occurrence of both a mental illness and a substance use
disorder (SUD). Lots of studies have analysed the integrated clinical approach, which involves
both psychiatry and toxicology medical experts. The purpose of this study is to analyse the socio-
demographic characteristics and treatment strategies of patients with DD in a rural area of Italy.
Patients and Methods: Clinical data of 750 patients were collected in 2016 through the
analysis of health plan records.
Results: The rate of co-occurring disorders is highly variable among people with SUD. In
the considered area, patients with DD are 24%, of these only 46.1% have been treated with
an integrated clinical program. Moreover, this percentage is further reduced (35.8%) if only
patients with heroin use disorder are considered.
Conclusion: A comprehensive revision of DD treatment is needed, especially for people
suffering from heroin use disorder and living in remote areas. Meticulous data analysis from
other addiction health services of rural areas could be necessary to identify a science-based
clinical intervention.
Keywords: dual diagnosis, integrated treatments, substance use disorder, social stigma, rural
populations
Introduction
The terms “co-occurring” or “dual diagnosis (DD)”mean the co-occurrence in the same
patient of both mental illness (MI) and substance use disorder (SUD).1 MI and SUD are
strongly connected, with high prevalence rates of DD among patients with SUD, even if
these epidemiological data vary significantly depending on multiple factors such as
geographical areas, reference population, study settings, study methodology; moreover,
the rate of people with DD seeking health treatment is influenced by several drivers,
making realistic epidemiological analysis even more challenging.2 In fact, according to
the epidemiological study conducted in 2011 by the Substance Abuse andMental Health
Services Administration, SAMHSA, only 44% of patients with DDwas treated for either
disorder.3 Just to report some examples of the high prevalence, and high prevalence
variability of DD among patients with SUD found by European studies, comorbidity of
schizophrenia and SUD prevalence is estimated to be 30–66%,4 comorbidity of depres-
sion and SUD prevalence is 12–80%,5 comorbidity of personality disorder and SUD
prevalence is 45%.6 Although the absence of a defined epidemiological prevalence rate,
the association between MI and SUD is clear.
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Many theories have been proposed to explain the link
between co-occurrence of SUD and MI, such as the inter-
action of genetic and environmental factors, which could
make an individual more predisposed to these disorders, or
the identification of MI as a risk factor for SUD or vice
versa.2 One other interesting explanation model could be
the “self-medication hypothesis”, which assumes that sub-
stances of abuse help individuals to relieve their psychia-
tric symptoms or negative emotions.7,8 This hypothesis is
still under discussion in the scientific literature.9–13 Once
discovered, the explanation of the link between co-
occurrence of SUD and MI would probably help to
develop prevention and treatment programs, but so far,
the complex relationship remains largely unknown and
poorly understood. Still, psychiatric problems are very
common among people with SUD, and this comorbidity
is a big challenge for medical doctors, in terms of preven-
tion and treatment.14–16
Primarily, the first problem is how to establish the
correct diagnosis, as sometimes symptoms due to sub-
stance’s withdrawal or intoxication cannot be clearly dis-
tinguished from those associated with MI or produced by
psychological conditions.17–18
Secondly, one of the major challenges is how to treat
individuals presenting both disorders. A universal agree-
ment on a guideline for the assessment and treatment of
the co-occurring disorder has still not been reached.19
Compared to patients with a single psychiatric disorder,
dual-diagnosed patients have more complicated treatment
processes and sometimes, in these patients, poorer compli-
ance and outcomes are expected as well as higher clinical
costs.20 In fact, DD is associated with increased psychiatric
hospitalisations and greater propensity to hazardous beha-
viours which lead, in turn, to higher risk of parenterally
transmitted diseases, unemployment and homelessness.2,21
The complexity of this comorbidity may need an integrated
medical management and a multiple clinical approach.22
A fully integrated treatment approach, which means
that patients are treated and managed by both psychiatrists
and toxicologists, so that both psychiatric and substance
use disorders are handled by specialized physicians with
shared treatment programs, could be more effective than
separate treatment plans;23–26 furthermore, uncoordinated
services are perceived by patients with DD as one of the
major difficulties to their recover.27 Separate programs
indeed have some disadvantages: the patients would be
in charge of managing two different services, which means
coordinating double appointments, and perhaps different
therapeutic approaches.2
In Italy, as in most countries, MI and SUD are mana-
ged separately: people with SUD are usually chronically
managed as outpatients by the drug-treatment territorial
services (Servizi Tossicodipendenze, SerT), whilst patients
with MI are addressed by mental health territorial services
(Centri di Salute Mentale, CMS).
Unfortunately, as the services are historically organized
separately, integrated treatments are not easy to implement;
moreover, these treatments require personnel, specific train-
ing, and adequate infrastructure which, in rural settings such
as some Italian areas, are even harder to organize.28
Common perception is that in comparison to urban set-
tings, rural communities are a safer environment in regards of
SUD,29 nevertheless some authors reported that rural status
confers several general disadvantages, such as less perceived
risk, reduced exposure to prevention messages and specific
disadvantages for health-care use measures, regardless of
poverty and health-care supply.30,31 Besides, Chasnoff and
colleagues reported that rural children aremore likely to have
mental health challenges, such as internalizing behaviours
and anxiety or mood disorders, than urban children.32
All patients enrolled in our study lived in an Italian
rural area suffering from socio-economic disadvantages:
unemployment (due to industrial crisis of the late 1980s)
and all medical and social problems linked to the elderly
population (28.1% of the inhabitants are aged over 65,
with a mean population age of 48.3).33
The aim of the current study is to analyse co-occurring
patient’s characteristics, their clinical and socio-demographic
situation, as well as clinical treatment strategies in the com-
munity addiction health centers (SerT). The first purpose was
to find out how the substance use is connected to the envir-
onment and to mental illness and secondly, we focused
specifically on all integrated clinical interventions proposed
to patients with DD.
Materials and Methods
A large retrospective, exploratory and descriptive survey
was conducted from April to December 2016 through data
collection from selected patient’s medical histories: we
enrolled patients with a current age ≥18 year and whose
diagnosis obtained from their medical records, satisfied the
DSM-5 diagnostic criteria for SUD (with the exception of
tobacco cigarettes) and another MI.
Age, sex, substance of abuse, mental illness, type of
treatment approach, and other main socio-demographic
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characteristics, such as educational level, marital status
and employment situation were considered.
All subjects included in this analysis were treated in one of
the four headquarters (Savona city, Albenga, Finale Ligure and
Cairo Montenotte) of Savona’s community addiction health
centers (SerT); Savona province, with a total population of
280,707 (ISTAT, 2016),34 is a rural area in the northwest of
Italy. The studywas approved by the institutional review board
“Regional ethic committee – Liguria Region”. Patient’s writ-
ten consent to review their medical records was collected and
the privacy of the participants was guaranteed as collected data
were anonymized and maintained with confidentiality. The
study was carried out in compliance with the Declaration of
Helsinki. A statistical analysis was performed using GraphPad
Prism 5 V.502. All statistical tests used the 5% level of
significance, and all p-values were two-tailed. Mean and per-
centages were used for descriptive statistics. Univariate com-
parisons for categorical data were made between groups using
Fisher’s exact test and Student’s t-test for continuous variables.
Results
Clinical histories of 750 patients with SUD were analysed
and 180 (24%) of them met the DSM-5 diagnostic criteria
for another MI satisfying therefore the definition of
patients with DD.
Subjects were predominantly male (n=126; 70%), Italians
(n= 168; 93.3%), with amean age of 45.7± 9.3 years (min= 22;
max=74). Only aminority of patients had one ormore children
(n=71; 39.4%) and 135 subjects (75%) were unmarried at the
time of clinical assessment. The majority of patients finished
primary school (n= 168; 93.3%) and 84 patients (46.7%) were
unemployed. Mean age, education level, state of employment,
marital status did not statistically differ between genders,
whilst women were more likely to have children than men
(p=0.0016). Only 71 subjects (39.4%) had familiarity with
SUD and/or MI (Table 1).
All enrolled patients had heroin, cocaine, cannabis, alco-
hol and/or a non-pharmacological addiction (gambling and
shopping). Specifically: 77 (42.8%) were dependent on
Table 1 Socio-Demographic and Descriptive Data
Total Women Men p*
N % N % N %
180 – 54 30 126 70
Socio-demographic characteristics
Mean age (years) 45.7 9.3 44.4 9.6 46.3 9.2 ns
Education (primary school) 168 93.3 50 92.6 118 93.7 ns
Unemployed 84 46.7 27 50 57 45.2 ns
Unmarried 135 75.0 42 77.8 93 73.8 ns
With children 71 39.4 31 57.4 40 31.7 p=0.0016
Familiarity 71 39.4 24 44.4 47 37.3 ns
Substances of abuse
CNS-d 77 42.8 21 38.9 56 44.4 ns
Multiple Substances 50 27.8 13 24.1 37 29.4 ns
Alcohol 33 18.3 10 18.5 23 18.3 ns
Cocaine 15 8.3 8 14.8 7 5.6 ns
Not-pharmacological 5 2.8 2 3.7 3 2.4 ns
Mental illness
MD 72 40.0 24 44.4 48 38.1 ns
PD 60 33.3 22 40.7 38 30.2 ns
SPD 24 13.3 1 1.9 23 18.3 p=0.0016
CD 17 9.4 3 5.6 14 11.1 ns
AD 7 3.9 4 7.4 3 2.4 ns
Integrated treatment 83 46.1 24 44.4 59 46.8 ns
Notes: *p<0.01 Fisher’s exact test; ns=not statistically significant.
Abbreviations: CNS-d, central nervous system disorder; Multiple Substances, patients dependent on more than one substance; MD, mood disorder; PD, personality
disorder; SPD, psychotic disorder; CD, cognitive disorder; AD, anxiety disorder.
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central nervous system depressants (CNS-d), respectively, 68
patients (88.3%) had heroin and 9 cannabis use disorder; 50
patients (27.8%) had a multiple substance addiction, respec-
tively, 25 subjects on heroin & cocaine, 21 on heroin &
cocaine & cannabis, 1 on cocaine & cannabis and 3 were
heroin & cannabis users, indeed basically almost all patients
dependent on more than one substance (49 subjects) had
heroin as one of their substance of abuse; 33 patients
(18.3%) had an alcohol use disorder; 15 (8.3%) were depen-
dent on cocaine; 5 patients (2.8%) had a non-pharmacological
addiction, respectively, 4 subjects had a gambling disorder
and 1 had a compulsive shopping disorder (Table 1).
In the same perspective the following psychiatric dis-
eases were identified: 72 patients (40%) were diagnosed
with a mood disorder (MD); 60 patients (33.3%) with
a personality disorder (PD); 24 (13.3%) with schizophrenia
or other psychotic disorder (SPD); 17 (9.4%) had a cognitive
disorder (CD) and only 7 patients (3.9%) had an anxiety
disorder (AD). Except for SPD, which was more common
among males (p=0.0016), psychiatric disease prevalence did
not statistically differ between genders.
The cross analysis of data shows that among patients
with CNS-d addiction (N = 77), the majority had a PD
(32.5%), then the remaining patients had a MD (31.2%),
a SPD (22.1%), a CD (10.4%) and only 3.9% had an AD
(Table 2). Among patients dependent on more than one
substance (N = 50), 44% had a PD and 36% a MD. The
remaining 20% of patients had CD (10%), SPD (6%)
and AD (4%). Among subjects with alcohol use disorder
(N = 33), the majority (57.6%) had a diagnosis of MD,
21.2% of PD, 9.1% of CD, 9.1% of SPD and only 3%
of AD (Table 2).
Among people with cocaine use disorder (N = 15),
53.3% had a diagnosis of MD; 33.3% of PD; both SPD
and CD were diagnosed in the 6.7% of patients.
Among the patients with a non-pharmacological addic-
tion (N = 5), three had a diagnosis of MD, one of AD and
a one of PD.
By comparing the prevalence of psychiatric diseases of
patients with different substance addiction (Post hoc analysis,
Table 2), we found that MD was more common in patients
with a non-pharmacological addiction, but a statistical sig-
nificant difference was detectable only between patients with
alcohol use disorder and patients with CNS-d addiction
(p<0.05); PD was more common in patients who had
a multiple substance addiction, especially in respect with
subjects with alcohol use disorder (p<0.05). Finally, SPD
was statistically more common in patients on CNS-d than
in patients with multiple substance addiction (p<0.05).
Only 83 subjects (46.1%) were steadily monitored and
treated with an integrated program; this percentage is
further reduced when considering only patients with CNS-
d addiction (33.8%) and patients dependent on more than
one substance (42%); patients dependent on cocaine or
alcohol were more frequently involved in integrated pro-
grams, with 73.3% and 69.7% of patients treated, respec-
tively. Statistical analysis showed the following significant
difference in rate of integrated treatment when comparing
the above-mentioned substance of abuse: subjects with
alcohol use disorder are more involved in integrated
Table 2 Cross Analysis of Data
1. CNS-d 2. Multiple Substances 3. Alcohol 4. Cocaine 5. Not-Pharm Total DD Post Hoc
N=77 N=50 N=33 N=15 N=5 N=180
N % N % N % N % N % N %
MD 24 31.2 18 36.0 19 57.6 8 53.3 3 60.0 72 40.0 1 vs 3*
PD 25 32.5 22 44.0 7 21.2 5 33.3 1 20.0 60 33.3 2 vs 3*
SPD 17 22.1 3 6.0 3 9.1 1 6.7 0 0.0 24 13.3 1 vs 2*
CD 8 10.4 5 10.0 3 9.1 1 6.7 0 0.0 17 9.4
AD 3 3.9 2 4.0 1 3.0 0 0 1 20.0 7 3.9
Integrated treatment 26 33.8 21 42.0 23 69.7 11 73.3 2 40.0 83 46.1 3 vs 1**; 3 vs 2 *;
4 vs 1*; 4 vs 2*
Notes: Statistical analysis was performed with Fisher’s exact test.*p<0.05; **p<0.01
Abbreviations: CNS-d, central nervous system disorder; Multiple Substances, patients dependent on more than one substance; DD, Dual Disorder; MD, mood disorder;
PD, personality disorder; SPD, psychotic disorder; CD, cognitive disorder; AD, anxiety disorder.
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treatments than patients on CNS-d (p<0.01) and patients
dependent on more than one substance (p<0.05), similarly,
subjects with cocaine use disorder are more involved than
patients on CNS-d (p<0.05) and patients dependent on more
than one substance (p<0.05).
Discussion
AEuropean review estimated the rate of comorbidity in people
with SUD to be as high as 50%,2 in our study, we found a DD
rate of 24%. As mentioned in the introduction, DD prevalence
rate varies considerably among different studies, because of
several biases, making data very difficult to compare: the DD
rate that we recorded, which seems to be far lower than the
mean European prevalence reported, becomes immediately
more in line with the 31% rate recorded in 2006 by the SIMI-
Italia data collection system, a national study which collected
data, similar to our study, in an Italian population of patients
attending SerT.2 The rate of DD could also have been influ-
enced by the socio-demographic characteristics of patients,
such as rate of unemployment, education, mean population
age and general economic conditions, as well as by the area of
residence (i.e. rural settings/urban areas); to this purpose,
available data suggest that a variety of socio/familiar/demo-
graphic factors are powerful predictors of difference in pre-
valence of SUD.35
Some authors report that rural populations have less social
risk factors and deprivations than urban inhabitants,36 which
could in part explain the particularly low prevalence of DD in
our study. Furthermore, in remote and isolated areas there is
a high rate of stigmatization,37–39 which may interfere with
access to all treatment services and treatment seeking beha-
viours related to SUD,29,37 so that our data could underesti-
mate the real extent of DD prevalence.
In addition to stigmatization, rural areas present also
further barriers to the delivery of clinical services in men-
tal health settings, such as economic, administrative and
organizational impediments.40
Regional organization and collaboration between
addiction health centers and mental health services are
crucial to implement integrated treatments, which are
demonstrated to be essential for improving the quality of
life and clinical outcomes of DD patients.41
Literature reports that unfortunately only a minority of
individuals with DD receive integrated interventions,24
intended as a multi-disciplinary treatment involving both
the psychiatric and substance use health services.
In Italy, the addiction health services, which provide
treatment in the areas of social work, psychology, nursing
and medical toxicology (substance use) for people with
SUD, do not usually include psychiatric health services.42
In line with the international literature, this study found
out that the majority of DD patients (53.9%), living in the
considered rural area, are only treated by the addiction
health center teams, whilst only 46% of patients were
treated with an integrated program.
Looking further into our data, we found out that access
to this superior type of treatment varies among patients,
depending on the substance of abuse. Specifically, inte-
grated programs involved mainly patients on cocaine or
alcohol (73.3% and 69.7% of patients, respectively), ver-
sus 42% of patients dependent on more than one substance
and 33.8% of patients on CNS-d.
This last group of patients included cannabis users, of
which 55.5% (5 out of 9 patients) were steadily monitored
with an integrated program, and patients with heroin
addiction, of which only 30.8% received the integrated
intervention (21 out of 68 patients). As almost all patients
dependent on more than one substance had heroin as one
of their substance of abuse (49 out of 50 subjects), the
percentage of all patients on heroin (adding “CNS-d” plus
“patients dependent on more than one substance”) receiv-
ing an integrated treatment is 35.8%. This suggests that
patients with co-occurrence heroin dependence, at least in
comparison with DD people addicted to alcohol or
cocaine, are less likely to receive integrated interventions.
Stigmatizing attitudes could be a possible explanation for
this exclusion. In general, stigmatizing attitudes in the popu-
lation may arise from the belief that addiction is a sort of
“vice”, not a proper mental illness, thereby making it mis-
understood. Woo et al. reported that patients in methadone
maintenance treatment are stigmatized, with higher experi-
ences of self- and perceived stigma associated with heroin
use.43 Moreover, health-care workers were identified as one
of the most important source of perceived stigma;44 this kind
of “health-care stigma” can negatively interfere with access of
heroin users to all health-care services.
Conclusion
An integrated approach forDDpatients, which is considered to
be more appropriate to improve adherence and clinical out-
come, appears to be hardly available especially for those
people living in remote areas and for patients with heroin
addiction. Anyway, meticulous data analysis from other addic-
tion health services from rural settings are necessary to analyse
the situation and hopefully to establish a gold standard of
practice.
Dovepress Milano et al








































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Author Contributions
All authors contributed to data analysis, drafting or revising
the article, gave final approval of the version to be published,
and agree to be accountable for all aspects of the work.
Disclosure
All authors declare that there are no known conflicts of
interest.
References
1. Brems C, Johnson ME, Wells RS, Burns R, Kletti N. Rates and sequelae
of the coexistence of substance use and other psychiatric disorders.
Int J Circumpolar Health. 2002;61:224–244. doi:10.3402/ijch.v61i3.
17456
2. EuropeanMonitoring Centre for Drugs and Drug Addiction (EMCDDA).
Comorbidity of substance use and mental disorders in Europe; 2015.
Available from: http://www.emcdda.europa.eu/attachements.cfm/att_
245096_EN_TDXD15019ENN.pdf. Accessed July 5, 2019.
3. Substance Abuse and Mental Health Services Administration
(SAMHSA). Results from the 2010 National Survey on Drug Use
and Health: summary of National Findings; 2011. Available from:
h t t p s : / / w ww. s a m h s a . g o v / d a t a / s i t e s / d e f a u l t / fi l e s /
NSDUHNationalFindingsResults2010-web/2k10ResultsRev/
NSDUHresultsRev2010.pdf. Accessed July 5, 2019.
4. Green AI. Schizophrenia and comorbid substance use disorder:
effects of antipsychotics. J Clin Psychiatry. 2005;66:21–26.
5. Torrens M, Martínez-Sanvisens D, Martínez-Riera R, Bulbena A,
Szerman N, Ruiz P. Dual diagnosis: focusing on depression and
recommendations for treatment. Addict Disord Their Treat.
2011;10:50–59. doi:10.1097/ADT.0b013e318215f322
6. Langås AM, Malt UF, Opjordsmoen S. In-depth study of personality
disorders in first-admission patients with substance use disorders.
BMC Psychiatry. 2012;12:180. doi:10.1186/1471-244X-12-180
7. Khantzian EJ. The self-medication hypothesis of addictive disorders:
focus on heroin and cocaine dependence. Am J Psychiatry.
1985;142:1259–1264.
8. Khantzian EJ. The self-medication hypothesis of substance use dis-
orders: a reconsideration and recent applications. Harv Rev
Psychiatry. 1997;4:231–244. doi:10.3109/10673229709030550
9. Dervaux A, Baylé FJ, Laqueille X, et al. Is substance abuse in schizo-
phrenia related to impulsivity, sensation seeking, or anhedonia? Am
J Psychiatry. 2001;158:492–494. doi:10.1176/appi.ajp.158.3.492
10. Goswami S, Mattoo SK, Basu D, Singh G. Substance-abusing schi-
zophrenics: do they self-medicate? Am J Addict. 2004;13:139–150.
doi:10.1080/10550490490435795
11. Bizzarri JV, Rucci P, Sbrana A, et al. Substance use in severe mental
illness: self-medication and vulnerability factors. Psychiatry Res.
2009;165:88–95. doi:10.1016/j.psychres.2007.10.009
12. Mariani JJ, Khantzian EJ, Levin FR. The self-medication hypothesis
and psychostimulant treatment of cocaine dependence: an update. Am
J Addict. 2014;23:189–193. doi:10.1111/vsu.v23.2
13. Pettersen H, Ruud T, Ravndal E, Landheim A. Walking the fine line:
self-reported reasons for substance use in persons with severe mental
illness. Int J Qual Stud Health Well-Being. 2013;8:21968. doi:10.3402/
qhw.v8i0.21968
14. Bizzarri JV, Casetti V, Panzani P, et al. Risky use and misuse of alcohol
and cigarettes in psychiatric inpatients: a screening questionnaire study.
Compr Psychiatry. 2016;70:9–16. doi:10.1016/j.comppsych.2016.05.011
15. Najt P, Fusar-Poli P, Brambilla P. Co-occurring mental and substance
abuse disorders: a review on the potential predictors and clinical
outcomes. Psychiatry Res. 2011;186:159–164. doi:10.1016/j.psychres.
2010.07.042
16. Martins SS, Gorelick DA. Conditional substance abuse and depen-
dence by diagnosis of mood or anxiety disorder or schizophrenia in
the US population. Drug Alcohol Depend. 2011;119:28–36.
doi:10.1016/j.drugalcdep.2011.05.010
17. Roncero C, Gómez-Baeza S, Vázquez JM, et al. Perception of
Spanish professionals on therapeutic adherence of dual diagnosis
patients. Actas Esp Psiquiatr. 2013;41:319–329.
18. Pani PP, Trogu E, Vigna-Taglianti F, et al. Psychopathological symp-
toms of patients with heroin addiction entering opioid agonist or
therapeutic community treatment. Ann Gen Psychiatry. 2014;13:35.
doi:10.1186/s12991-014-0035-x
19. Berenz EC, Coffe SF. Treatment of co-occurring posttraumatic stress
disorder and substance use disorders. Curr Psychiatry Rep.
2012;14:469–477. doi:10.1007/s11920-012-0300-0
20. Sterling S, Chi F, Hinman A. Integrating care for people with
co-occurring alcohol and other drug, medical, and mental health
conditions. Alcohol Res Health. 2011;33:338–349.
21. Di Lorenzo R, Galliani A, Guicciardi A, et al. A retrospective ana-
lysis focusing on a group of patients with dual diagnosis treated by
both mental health and substance use services. Neuropsychiatr Dis
Treat. 2014;10:1479–1488. doi:10.2147/NDT.S65896
22. Kêdoté MN, Brousselle A, Champagne F. Use of health care services
by patients with co-occurring severe mental illness and substance use
disorders. Ment Health Subst Use. 2008;1:216–227. doi:10.1080/
17523280802274886
23. Green CA, Yarborough MT, Polen MR, Janoff SL, Yarborough BJH.
Dual recovery among people with serious mental illnesses and sub-
stance problems: a qualitative analysis. J Dual Diagn.
2015;11:33–41. doi:10.1080/15504263.2014.975004
24. Drake RE, O’Neal EL, Wallach MA. A systematic review of psycho-
social research on psychosocial interventions for people with
co-occurring severe mental and substance use disorders. J Subst
Abuse Treat. 2008;34:123–138. doi:10.1016/j.jsat.2007.01.011
25. Ziedonis DM, Smelson D, Rosenthal RN, et al. Improving the care of
individuals with schizophrenia and substance use disorders: consen-
sus recommendations. J Psychiatr Pract. 2005;11:315–339.
doi:10.1097/00131746-200509000-00005
26. Dixon LB, Dickerson F, Bellack AS, et al. The 2009 schizophrenia PORT
psychosocial treatment recommendations and summary statements.
Schizophr Bull. 2010;36:48–70. doi:10.1093/schbul/sbp115
27. Ness O, Borg M, Davidson L. Facilitators and barriers in dual
recovery: a literature review of first-person perspectives. Adv Dual
Diagn. 2014;7:107–117. doi:10.1108/ADD-02-2014-0007
28. Murthy P, Mahadevan J, Chand PK. Treatment of substance use disorders
with co-occurring severe mental health disorders. Curr Opin Psychiatry.
2019;32:293–299. doi:10.1097/YCO.0000000000000510
29. Milano G, Saenz E, Clark N, et al. Report on the International
Workshop on Drug Prevention and Treatment in Rural Settings
Organized by United Nation Office on Drugs and Crime (UNODC)
and World Health Organization (WHO). Subst Use Misuse.
2017;52:1801–1807. doi:10.1080/10826084.2017.1306564
30. Caldwell JT, Ford CL, Wallace SP, Wang MC, Takahashi LM.
Intersection of living in a rural versus urban area and race/ethnicity
in explaining access to health care in the United States. Am J Public
Health. 2016;106:1463–1469. doi:10.2105/AJPH.2016.303212
31. Monnat SM, Rigg KK. Examining rural/urban differences in pre-
scription opioid misuse among US adolescents. J Rural Health.
2016;32:204–218. doi:10.1111/jrh.2016.32.issue-2
32. Chasnoff IJ, Telford E, Wells AM, King L. Mental health disorders
among children within child welfare who have prenatal substance
exposure: rural vs. urban populations. Child Welfare. 2015;94:53–70.
33. ISTAT, National Institute of Statistics. Available from: http://dati.istat.it/
Index.aspx?DataSetCode=DCIS_INDDEMOG1#. Accessed October 14,
2019.
34. ISTAT, National Institute of Statistics. Available from: http://dati.
istat.it/Index.aspx?QueryId=18967. Accessed July 5, 2019.
Milano et al Dovepress
submit your manuscript | www.dovepress.com
DovePress






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
35. Judd FK, Jackson HJ, Komiti A, Murray G, Hodgins G, Fraser C. High
prevalence disorders in urban and rural communities. Aust
N Z J Psychiatry. 2002;36:104–113. doi:10.1046/j.1440-1614.2002.
00986.x
36. Mueser KT, Essock SM, Drake RE, Wolfe RS, Frisman L. Rural and
urban differences in patients with a dual diagnosis. Schizophr Res.
2001;48:93–107. doi:10.1016/S0920-9964(00)00065-7
37. Browne T, Priester MA, Clone S, Iachini A, DeHart D, Hock R. Barriers
and facilitators to substance use treatment in the rural south: a qualitative
study. J Rural Health. 2016;32:92–101. doi:10.1111/jrh.12129
38. Benoit C, McCarthy B, Jansson M. Stigma, sex work, and substance
use: a comparative analysis. Sociol Health Illn. 2015;37:437–451.
doi:10.1111/shil.2015.37.issue-3
39. King R. Science over stigma saving lives—implementation of
Naloxone use in the school setting. NASN School Nurse.
2016;31:96–101. doi:10.1177/1942602X16628890
40. Guerrero EG, Padwa H, Lengnick-Hall R, Kong Y, Perrigo JL.
Leadership and licensure for drug treatment and the implementation
of co-occurring disorder treatment in community mental health
centers. Community Ment Health J. 2015;51:554–566. doi:10.1007/
s10597-015-9886-0
41. Lozano ÓM, Rojas AJ, Fernández Calderón F. Psychiatric comorbid-
ity and severity of dependence on substance users: how it impacts on
their health-related quality of life? J Ment Health. 2017;26:119–126.
doi:10.1080/09638237.2016.1177771
42. Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D. Substance
misuse in patients with schizophrenia: epidemiology and management.
Drugs. 2002;62:743–755. doi:10.2165/00003495-200262050-00003
43. Woo J, Bhalerao A, Bawor M, et al. “Don’t judge a book its cover”:
a qualitative study of methadone patients’ experiences of stigma.
Subst Abuse. 2017;11:1178221816685087.
44. Garcia-Portilla MP, Bobes-Bascaran MT, Bascaran MT, Saiz PA,
Bobes J. Long term outcomes of pharmacological treatments for
opioid dependence: does methadone still lead the pack? Br J Clin
Pharmacol. 2014;77:272–284. doi:10.1111/bcp.2014.77.issue-2
Neuropsychiatric Disease and Treatment Dovepress
Publish your work in this journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing
on concise rapid reporting of clinical or pre-clinical studies on a
range of neuropsychiatric and neurological disorders. This journal is
indexed on PubMed Central, the ‘PsycINFO’ database and CAS, and
is the official journal of The International Neuropsychiatric
Association (INA). The manuscript management system is comple-
tely online and includes a very quick and fair peer-review system,
which is all easy to use. Visit http://www.dovepress.com/testimo-
nials.php to read real quotes from published authors.
Submit your manuscript here: https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Dovepress Milano et al








































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
